Two year persistent treatment effect in reducing nasal symptoms of cat allergy after 4 doses of Cat-PAD, the first in a new class of synthetic peptide immuno-regulatory epitopes

Por Hafner, Roderick, Couroux, Peter, Armstrong, Kristen, Patel, Deepen, Larche, Mark, Haumann, Brett
Publicado em 2013

A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease

Por Pudi, Krishna K., Barnes, Chris N., Moran, Edmund J., Haumann, Brett, Kerwin, Edward
Publicado no Respir Res (2017)

Evaluation of an ambulatory system for the quantification of cough frequency in patients with chronic obstructive pulmonary disease

Por Coyle, Michael A, Keenan, Desmond B, Henderson, Linda S, Watkins, Michael L, Haumann, Brett K, Mayleben, David W, Wilson, Michael G
Publicado em 2005

Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma

Por Woodcock Ashley, Bleecker Eugene R, Busse William W, Lötvall Jan, Snowise Neil G, Frith Lucy, Jacques Loretta, Haumann Brett, Bateman Eric D
Publicado em 2011-12-01

Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial

Por Woodcock, Ashley, Bateman, Eric D, Busse, William W, Lötvall, Jan, Snowise, Neil G, Forth, Richard, Jacques, Loretta, Haumann, Brett, Bleecker, Eugene R
Publicado em 2011

Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma

Por Woodcock, Ashley, Bleecker, Eugene R, Busse, William W, Lötvall, Jan, Snowise, Neil G, Frith, Lucy, Jacques, Loretta, Haumann, Brett, Bateman, Eric D
Publicado em 2011